2024PatientSocioeconomic
Medication Adherence and Associated Factors Among Hypertensive Patients in Indonesian Primary Care: An Application of the UMAS Framework
Santoso A, Rahayu P, Wijaya T, et al.
Journal of Hypertension Research·Vol 14, 2024
This cross-sectional study assessed medication adherence among 320 hypertensive patients in West Java primary care facilities. Using the UMAS instrument, the study identified forgetfulness and financial constraints as the leading barriers, consistent with the LMIC-focused design of the scale.
2024Socioeconomic
Socioeconomic Barriers to Diabetes Medication Adherence in Rural West Java: A Mixed-Methods Study Using UMAS Domain IV
Nugraha Y, Pratama RD, Alfian SD
Diabetes & Metabolic Syndrome: Clinical Research & Reviews·Vol 18, 2024
A mixed-methods investigation exploring socioeconomic determinants of medication non-adherence in Type 2 Diabetes patients in rural settings. UMAS Domain IV revealed insurance gaps and transportation barriers as critical factors, informing targeted policy interventions.
2024MedicalValidation
Cross-Cultural Adaptation and Validation of the UMAS Instrument in Filipino Chronic Disease Patients: A Psychometric Study
Reyes MJ, Santos LC, Bautista KA, et al.
Philippine Journal of Health Research & Development·Vol 28, 2024
First external validation of UMAS outside Indonesia. The Filipino adaptation demonstrated strong internal consistency (Cronbach's α = 0.87) and confirmatory factor structure across 4 domains in a sample of 412 patients with hypertension, diabetes, and dyslipidemia.
2024HealthcareSocioeconomic
Medication Adherence Patterns in Malaysian Dyslipidemia Patients: An UMAS-Based Assessment of System and Economic Barriers
Lee KW, Chong YL, Ahmad Z, Tan SK
Lipids in Health and Disease·Vol 23, 2024
A cross-sectional study (n=310) applying UMAS to dyslipidemia patients in Malaysian secondary care. Out-of-pocket medication costs and suboptimal patient counseling emerged as co-dominant barriers, reinforcing UMAS's dual capacity to capture both system and economic contributors to non-adherence.
2023Healthcare
Healthcare Facility Factors and Medication Adherence in Community Health Centers: Insights from UMAS Domain III in Urban Indonesia
Pratama RD, Hendrawati S, Kurniawan A
BMC Primary Care·Vol 24, 2023
A prospective observational study in 8 Puskesmas in Bandung examining how healthcare system factors — drug stock-outs, counseling quality, and waiting times — affect medication adherence in chronic disease patients. UMAS Domain III showed highest discriminatory power for system-level interventions.
2023PatientMedical
Comparing UMAS with the Morisky Medication Adherence Scale (MMAS-8) in Cardiovascular Outpatients: A Head-to-Head Psychometric Comparison
Ibrahim MA, Hassan NN, Al-Rashid KM
Cardiovascular Therapeutics·Vol 2023, 2023
Comparative analysis of UMAS vs MMAS-8 in 280 cardiovascular outpatients in Malaysia. UMAS demonstrated superior discriminant validity in LMIC contexts, particularly in capturing socioeconomic and system-level barriers that MMAS-8 does not address.
2023Socioeconomic
Structural Barriers to Anti-Hypertensive Medication Adherence in Sub-Saharan Africa: A Systematic Application of the UMAS Socioeconomic Domain
Osei-Bonsu K, Mensah EK, Asante FA
Global Health: Science and Practice·Vol 11, 2023
The first application of UMAS in Sub-Saharan Africa, conducted in rural Ghana with 195 hypertensive patients. Findings underscore the generalizability of UMAS Domain IV across diverse LMIC contexts, with cultural and financial barriers emerging as dominant predictors of non-adherence.
2023MedicalValidation
Internal Validation of the UMAS Indonesian Version in Type 2 Diabetes Mellitus Patients at Dr. Sardjito Hospital
Wijaya T, Lestari R, Soekanto A, Alfian SD
Indonesian Biomedical Journal·Vol 15, 2023
Replication and internal validation study confirming the 4-factor structure of UMAS in a Type 2 DM population (n=245). Confirmatory factor analysis supported excellent model fit. Medical factor domain showed highest factor loading in patients with polypharmacy regimens.